When was DNAtrix founded?

DNAtrix was founded in 2005 and raised its 1st funding round 3 years after it was founded.

Where is DNAtrix located?

DNAtrix is headquartered in Houston, United States.

How many employees does DNAtrix have?

As of May 31, 2026, the latest employee count at DNAtrix is 4.

Is DNAtrix a funded company?

DNAtrix is a funded company, having raised a total of $43M across 11 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Nov 19, 2008.

When was the latest funding round of DNAtrix?

DNAtrix's latest funding was a $***** Grant (prize money) round on Sep 01, 2022, with participation from 1 investor. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $1.14B in funding in 2026 to date.

Where does DNAtrix rank among its competitors?

DNAtrix ranks 1002nd amongst 3270 active competitors, of which 1126 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of DNAtrix?

DNAtrix's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

DNAtrix - 2026 Company Profile, Team, Funding & Competitors

Company Details

DNAtrix is a clinical stage company developing virus-driven immunotherapies for cancer. Its lead product, DNX-2401 is a conditionally replicative oncolytic virus being studied in clinical trials for recurrent glioblastoma (brain cancer) and is in Phase 3. Its pipeline includes viruses armed with potent immunomodulatory molecules that augment a patient’s immune system to trigger an aggressive anti-tumor T-cell response .

Website: dnatrix.com
Social

Key Metrics

Founded Year

2005

Location

Houston, United States

Stage

Series C

Total Funding

$43M in 11 rounds

Latest Funding Round

Grant (prize money), Sep 01, 2022, $*****

Investors

Morningside & 8 more

Ranked

1002^nd among 3270 active competitors

Employee Count

4 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3005 more

View DNAtrix's full profile

DNAtrix has raised a total funding of $43M over 11 rounds. Its first funding round was on Nov 19, 2008. Its latest funding round was a Grant (prize money) round on Sep 01, 2022 for $*****. 1 investor participated in its latest round. DNAtrix has 9 institutional investors.

Here is the list of recent funding rounds of DNAtrix:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 01, 2022	2849134	Grant (prize money)	4828372	2554496	1952040	7940813
Sep 12, 2018	4149950	Series C	4036958	6210817	7547851	4426015
Aug 04, 2016	9712082	Grant (prize money)	5420189	6408857	2979460	FDA

Access funding benchmarks and valuations. Sign up today!

View details of DNAtrix's funding rounds and investors

DNAtrix's employee count trend

DNAtrix has 4 employees as of May 26. Here is DNAtrix's employee count trend over the years:

Uncover DNAtrix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of DNAtrix include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of DNAtrix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
1002nd	DNAtrix 2005, Houston (United States), Series C	Oncolytic virus platform for treating malignant glioma.	$43M	Morningside, FDA & 7 others	41/100